Evidence map›Paper›PMID 26746999›Full record

ArticleJournal of the American Heart Association2016

Testosterone Antagonizes Doxorubicin-Induced Senescence of Cardiomyocytes.

Paola Altieri, Chiara Barisione, Edoardo Lazzarini, Anna Garuti, Gian Paolo Bezante, Marco Canepa, Paolo Spallarossa, Carlo Gabriele Tocchetti, Sveva Bollini, Claudio Brunelli and 1 more

Open access · goldAbstract read
In one paragraph

Article in Journal of the American Heart Association, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 1 pooled it
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Paola AltieriLaboratory of Cardiovascular Biology, Department of Internal Medicine, University of Genova, Italy (P.A., C.B., E.L., G.P.B., M.C., P.S., C.B., P.A.).
Chiara BarisioneLaboratory of Cardiovascular Biology, Department of Internal Medicine, University of Genova, Italy (P.A., C.B., E.L., G.P.B., M.C., P.S., C.B., P.A.).
Edoardo LazzariniLaboratory of Cardiovascular Biology, Department of Internal Medicine, University of Genova, Italy (P.A., C.B., E.L., G.P.B., M.C., P.S., C.B., P.A.).
Anna GarutiLaboratory of Cellular Therapies, Department of Internal Medicine, University of Genova, Italy (A.G.).
Gian Paolo BezanteLaboratory of Cardiovascular Biology, Department of Internal Medicine, University of Genova, Italy (P.A., C.B., E.L., G.P.B., M.C., P.S., C.B., P.A.).
Marco CanepaLaboratory of Cardiovascular Biology, Department of Internal Medicine, University of Genova, Italy (P.A., C.B., E.L., G.P.B., M.C., P.S., C.B., P.A.).
Paolo SpallarossaLaboratory of Cardiovascular Biology, Department of Internal Medicine, University of Genova, Italy (P.A., C.B., E.L., G.P.B., M.C., P.S., C.B., P.A.).
Carlo Gabriele TocchettiDivision of Internal Medicine, Department of Translational Medical Sciences, Federico II University, Napoli, Italy (C.G.T.).
Sveva BolliniRegenerative Medicine Laboratory, Department of Experimental Medicine, University of Genova, Italy (S.B.).
Claudio BrunelliLaboratory of Cardiovascular Biology, Department of Internal Medicine, University of Genova, Italy (P.A., C.B., E.L., G.P.B., M.C., P.S., C.B., P.A.).
Pietro AmeriLaboratory of Cardiovascular Biology, Department of Internal Medicine, University of Genova, Italy (P.A., C.B., E.L., G.P.B., M.C., P.S., C.B., P.A.).
University of Genoa · ITFederico II University Hospital · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChronic cardiotoxicity is less common in male than in female patients receiving doxorubicin and other anthracyclines at puberty and adolescence. We hypothesized that this sex difference might be secondary to distinct activities of sex hormones on cardiomyocyte senescence, which is thought to be central to the development of long-term anthracycline cardiomyopathy. METHODS AND

resultsH9c2 cells and neonatal mouse cardiomyocytes were exposed to doxorubicin with or without prior incubation with testosterone or 17β-estradiol, the main androgen and estrogen, respectively. Testosterone, but not 17β-estradiol, counteracted doxorubicin-elicited senescence. Downregulation of telomere binding factor 2, which has been pinpointed previously as being pivotal to doxorubicin-induced senescence, was also prevented by testosterone, as were p53 phosphorylation and accumulation. Pretreatment with the androgen receptor antagonist flutamide, the phosphatidylinositol 3 kinase inhibitor LY294002, and the nitric oxide synthase inhibitor L-NG-nitroarginine methyl ester abrogated the reduction in senescence and the normalization of telomere binding factor 2 levels attained by testosterone. Consistently, testosterone enhanced the phosphorylation of AKT and nitric oxide synthase 3. In H9c2 cells, doxorubicin-stimulated senescence was still observed up to 21 days after treatment and increased further when cells were rechallenged with doxorubicin 14 days after the first exposure to mimic the schedule of anthracycline-containing chemotherapy. Remarkably, these effects were also inhibited by testosterone.

conclusionsTestosterone protects cardiomyocytes against senescence caused by doxorubicin at least in part by modulating telomere binding factor 2 via a pathway involving the androgen receptor, phosphatidylinositol 3 kinase, AKT, and nitric oxide synthase 3. This is a potential mechanism by which pubescent and adolescent boys are less prone to chronic anthracycline cardiotoxicity than girls.

Indexed as

AnimalsAnimals, NewbornAntibiotics, AntineoplasticCardiomyopathiesCardiotoxicityCell LineCell ProliferationCellular SenescenceCytoprotectionDose-Response Relationship, DrugDoxorubicinEstradiolFemaleMaleMice, Inbred C57BLMyocytes, CardiacAntibiotics, AntineoplasticAR protein, mouseDoxorubicinEstradiolNitric Oxide Synthase Type IIINos3 protein, mouseNos3 protein, ratPhosphatidylinositol 3-KinaseProto-Oncogene Proteins c-aktReceptors, AndrogenTelomeric Repeat Binding Protein 2Testosteronecardiotoxicitydoxorubicinsenescencesextestosterone

Identifiers

PMID26746999
PMCPMC4859360
OpenAlexW2225428464

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.